HFA Premium Access

Estimation of the target population of a selective cardiac myosin inhibitor for hypertrophic obstructive cardiomyopathy: Real-life data from the French REMY register.

Congress Presentation

About the speaker

Mrs Tanya Muresan

European Hospital Georges Pompidou, Paris (France)
0 follower

6 more presentations in this session

Patient-reported outcome measures in wild-type and variant cardiac transthyretin amyloidosis: the ITALY (impact of transthyretin amyloidosis on life quality) study

Speaker: Doctor A. Aimo (Pisa, IT)


Echocardiography machine learning based to improve detection of transthyretin cardiac amyloidosis: the R3M algorithm

Speaker: Doctor A. Fraix (Nancy, FR)


Hypertrophic cardiomyopathy in female patients is associated with symptomatic heart failure and worse functional and exercise capacity

Speaker: Doctor Y. Wasserstrum (Ramat Gan, IL)


Relative apical longitudinal strain: a powerful tool to predict outcomes in transthyretin amyloid cardiomyopathy

Speaker: Doctor M. Castro (Guimaraes, PT)


A novel myocardium functional echocardiographic parameter, left ventricular myocardial work, associates with sudden cardiac risk score in patients with hypertrophic cardiomyopathy

Speaker: Doctor G. Racz (Szeged, HU)


Access the full session

Myocardial disease - hypertrophic cardiomyopathy 3

Speakers: Mrs T. Muresan, Doctor A. Aimo, Doctor A. Fraix, Doctor Y. Wasserstrum, Doctor M. Castro...

About the event


Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb